Difficulty: Medium
Average Score: 93%
Practice
All of the following statements regarding rosiglitazone are correct EXCEPT:
Correct answer
A
Rationale
In this CNS Pharmacology Drug Quiz question, the correct answer is A) It promotes insulin release from the pancreatic beta-cells. This statement is incorrect because rosiglitazone does not directly promote insulin release from pancreatic beta-cells.
Rosiglitazone is a thiazolidinedione used in the management of type 2 diabetes mellitus. It works by increasing insulin sensitivity in peripheral tissues, such as muscle and adipose tissue, rather than promoting insulin release from beta-cells. Therefore, statements B, C, and D are correct.
In an educational context, understanding the mechanism of action of drugs is crucial for healthcare professionals to make informed decisions regarding patient care. By knowing that rosiglitazone acts as an insulin sensitizer and can counteract insulin resistance, healthcare providers can appropriately prescribe this medication to manage type 2 diabetes effectively. This knowledge also helps in monitoring for side effects and drug interactions, ensuring patient safety and optimal outcomes.
Rosiglitazone is a thiazolidinedione used in the management of type 2 diabetes mellitus. It works by increasing insulin sensitivity in peripheral tissues, such as muscle and adipose tissue, rather than promoting insulin release from beta-cells. Therefore, statements B, C, and D are correct.
In an educational context, understanding the mechanism of action of drugs is crucial for healthcare professionals to make informed decisions regarding patient care. By knowing that rosiglitazone acts as an insulin sensitizer and can counteract insulin resistance, healthcare providers can appropriately prescribe this medication to manage type 2 diabetes effectively. This knowledge also helps in monitoring for side effects and drug interactions, ensuring patient safety and optimal outcomes.